Molecular Profiling of Malignant Pleural Effusion in Metastatic Non-Small-Cell Lung Carcinoma The Effect of Preanalytical Factors

被引:54
|
作者
Carter, Jamal [1 ]
Miller, James Adam [1 ]
Feller-Kopman, David [2 ]
Ettinger, David [3 ]
Sidransky, David [3 ]
Maleki, Zahra [1 ]
机构
[1] Johns Hopkins Univ Hosp, Dept Pathol, Div Cytopathol, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ Hosp, Dept Pulmonol, Baltimore, MD 21287 USA
[3] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD USA
关键词
molecular profiling; malignant pleural effusion; non-small-cell lung carcinoma; lung adenocarcinoma; preanalytical factors; CANCER PATIENTS; EGFR MUTATIONS; FLUID; VOLUME; GUIDELINE; DIAGNOSIS; SELECTION; SURVIVAL; KRAS;
D O I
10.1513/AnnalsATS.201609-709OC
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Rationale: Non-small-cell lung cancer (NSCLC)-associated malignant pleural effusions (MPEs) are sometimes the only available specimens for molecular analysis. Objectives: This study evaluatesdiagnostic yield of NSCLC-associated MPE, its adequacy for molecular profiling and the potential influence of MPE volume/cellularity on the analytic sensitivity of our assays. Methods: Molecular results of 50 NSCLC-associated MPE cases during a 5-year period were evaluated. Molecular profiling was performed on cell blocks and consisted of fluorescent in situ hybridization (FISH) for ALK gene rearrangements and the following sequencing platforms: Sanger sequencing (for EGFR) and high-throughput pyrosequencing (for KRAS and BRAF) during the first 4 years of the study period, and targeted next-generation sequencing performed thereafter. Results: A total of 50 NSCLC-associated MPE cases were identified where molecular testing was requested. Of these, 17 cases were excluded: 14 cases (28%) due to inadequate tumor cellularity and 3 cases due to unavailability of the slides to review. A total of 27 out of 50 MPE cases (54%) underwent at least EGFR and KRAS sequencing and FISH for ALK rearrangement. Of the 27 cases with molecular testing results available, a genetic abnormality was detected in 16 cases (59%). The most common genetic aberrations identified involved EGFR (9) and KRAS (7). Six cases had ALK FISH only, of which one showed rearrangement. MPE volume was not associated with overall cellularity or tumor cellularity (P = 0.360). Conclusions: Molecular profiling of MPE is a viable alternative to testing solid tissue in NSCLC. This study shows successful detection of genetic aberrations in 59% of samples with minimal risk of false negative.
引用
收藏
页码:1169 / 1176
页数:8
相关论文
共 50 条
  • [1] Molecular Profiling of Malignant Pleural Effusion in Metastatic Non-Small Cell Lung Carcinoma
    Carter, Jamal H.
    Miller, James A.
    Maleki, Zahra
    [J]. LABORATORY INVESTIGATION, 2016, 96 : 94A - 94A
  • [2] Molecular Profiling of Malignant Pleural Effusion in Metastatic Non-Small Cell Lung Carcinoma
    Carter, Jamal H.
    Miller, James A.
    Maleki, Zahra
    [J]. MODERN PATHOLOGY, 2016, 29 : 94A - 94A
  • [3] Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non-Small-Cell Lung Cancer
    Morgensztern, Daniel
    Waqar, Saiama
    Subramanian, Janakiraman
    Trinkaus, Kathryn
    Govindan, Ramaswamy
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (10) : 1485 - 1489
  • [4] The Efficacy of Pleurodesis on Non-Small-Cell Lung Cancer with Large Malignant Pleural Effusion
    Kimura, Madoka
    Naito, Tateaki
    Kenmotsu, Hirokazu
    Nakamura, Yukiko
    Tsuya, Asuka
    Kaira, Kyoichi
    Murakami, Haruyasu
    Takahashi, Toshiaki
    Endo, Masahiro
    Yamamoto, Nobuyuki
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S402 - S402
  • [5] Surgical intervention for non-small-cell lung cancer with minimal malignant pleural effusion
    Iwasaki, Masashi
    Shimomura, Masanori
    Ishihara, Shunta
    Yamaguchi, Tadanori
    Kishimoto, Mitsuo
    Ii, Tsunehiro
    Inoue, Masayoshi
    [J]. SURGERY TODAY, 2023, 53 (06) : 655 - 662
  • [6] Surgical intervention for non-small-cell lung cancer with minimal malignant pleural effusion
    Masashi Iwasaki
    Masanori Shimomura
    Shunta Ishihara
    Tadanori Yamaguchi
    Mitsuo Kishimoto
    Tsunehiro Ii
    Masayoshi Inoue
    [J]. Surgery Today, 2023, 53 : 655 - 662
  • [7] Vandetanib and Indwelling Pleural Catheter for Non-Small-Cell Lung Cancer With Recurrent Malignant Pleural Effusion
    Massarelli, Erminia
    Onn, Amir
    Marom, Edith M.
    Alden, Christine M.
    Liu, Diane D.
    Tran, Hai T.
    Mino, Barbara
    Wistuba, Ignacio I.
    Faiz, Saadia A.
    Bashoura, Lara
    Eapen, George A.
    Morice, Rodolfo C.
    Lee, J. Jack
    Hong, Waun K.
    Herbst, Roy S.
    Jimenez, Carlos A.
    [J]. CLINICAL LUNG CANCER, 2014, 15 (05) : 379 - 386
  • [8] Surgery for Non-Small-Cell Lung Cancer with Malignant Minor Pleural Effusion Detected on Thoracotomy
    Yokota, T.
    Ikeda, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2382 - S2382
  • [9] CHEMOTHERAPY OF METASTATIC NON-SMALL-CELL CARCINOMA OF THE LUNG
    RUCKDESCHEL, JC
    [J]. HEMATOLOGICAL ONCOLOGY, 1992, 10 (01) : 25 - 30
  • [10] Molecular Profiling for Supernatants and Matched Cell Pellets of Pleural Effusions in Non-Small-Cell Lung Cancer
    Xiang, Chan
    Huo, Mingfei
    Ma, Shengji
    Guo, Lianying
    Zhao, Ruiying
    Teng, Haohua
    Zhang, Jie
    Han, Yuchen
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (04): : 513 - 522